The effects of @entity2198 ( @entity2198 ) of the primary vestibular afferents on synaptic transmission in the ventral part of the medial vestibular nuclei (vMVN) were studied during postnatal development and compared with the changes in the expression of the group I metabotropic @entity2227 receptor (mGluR) subtypes, @entity9446 and @entity10092 . During the first stages of development, @entity2198 always induced a @entity10092 - and GABAA-dependent long-term @entity308 (LTD) which did not require @entity143 receptor and @entity9446 activation. The probability of inducing LTD decreased progressively throughout the development and it was zero at about the end of the second postnatal week. Conversely, long-term potentiation (LTP) appeared at the beginning of the second week and its occurrence increased to reach the adult value at the end of the third week. Of interest, the sudden change in the LTP frequency occurred at the time of eye opening, about the end of the second postnatal week. LTP depended on @entity143 receptor and @entity9446 activation. In parallel with the modifications in synaptic plasticity, we observed that the expression patterns and localizations of @entity10092 and @entity9446 in the medial vestibular nuclei (MVN) changed during postnatal development. At the earlier stages the @entity9446 expression was minimal, then increased progressively. In contrast, @entity10092 expression was initially high, then decreased. While @entity9446 was exclusively localized in neuronal compartments and concentrated at the postsynaptic sites at all stages observed, @entity10092 was found mainly in neuronal compartments at immature stages, then preferentially in glial compartments at mature stages. These results provide the first evidence for a progressive change from LTD to LTP accompanied by a distinct maturation expression of @entity9446 and @entity10092 during the development of the MVN.

Developmental shift from long-term @entity308 to long-term potentiation in the rat medial vestibular nuclei: role of group I metabotropic XXXX receptors.

@entity2198 :: ('MESH:D006316', 'Disease') :: ['high frequency stimulation', 'HFS'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity10092 :: ('14805(Tax:10090)', 'Gene') :: ['mGluR5'] @entity9446 :: ('14799(Tax:10090)', 'Gene') :: ['mGluR1'] @entity143 :: ('CHEBI:6121', 'Chemical') :: ['NMDA']
@entity2227 :: (CHEBI:29987,Chemical) :: ['glutamate']
